Mesenchymal-epithelial transition factor amplification correlates with adverse pathological features and poor clinical outcome in colorectal cancer.

Background: Colorectal cancer (CRC) is the third most common cancer and the second most common cause of cancer-related mortality worldwide. Mesenchymal-epithelial transition factor () gene participates in multiple tumor biology and shows clinical potential for pharmacological manipulation in tumor treatment. amplification has been reported in CRC, but data are very limited.